VIVO Cannabis Inc. Subscribes to Strainprint Technologies to Maximize Patient Treatment Experience

TORONTO, Sept. 24, 2018 /CNW/ - Strainprint, the leader in cannabis data and analytics, is pleased to announce that VIVO Cannabis Inc. (TSXV: VIVO) is the latest top tier Canadian licensed producer to subscribe to Strainprint Analytics. VIVO is a leading, vertically-integrated, cannabis business with a collection of premium brands targeting unique consumer segments and needs across both medical and recreational channels, both in Canada and other international markets.

VIVO will leverage this strategic subscription to coincide with the launch of their Beacon Medical brand, a standardized pharma-grade cannabis that's clean, consistent and repeatable — qualities sought by physicians and patients, which stands for setting patients on the clearest path to treatment.

"With a company tagline like 'living life', VIVO clearly embodies the same passion, focus and commitment as Strainprint with the ultimate goal to improve lives through the use of quality cannabis products and services. We are delighted that they have chosen to work with us" said Strainprint CEO, Andrew Muroff.

The Strainprint experience helps create clarity for patients and is right in line with this mission. Beacon Medical plans to leverage data insights from the app, encourage more patients to track their treatment sessions for the best results and provide redeemable discounts and merchandise for engaged users on a custom-branded version of the app. Strainprint can provide access to more than 30 million data points on strain efficacy from more than 800,000 anonymous personal health records - the largest and most granular scientific data set of its kind in the world.

"We support the spirit of Strainprint, which encourages patients to be mindful of their treatments in a way that's made easy by their highly intuitive app," said Sung Kang, Chief Marketing Officer of Vivo Cannabis. "We are always looking for ways to provide value-added services to our patients, and using Strainprint's robust database of dosing experiences will help us provide useful information to both patients and health care professionals."

About Strainprint™

Founded in Toronto in 2016, Strainprint^™ Technologies Ltd. is the leading demand-side cannabis data and analytics company. With the world's largest longitudinal, observational data-set of its kind and a mission to advance the scientific understanding of cannabis and its legitimization as a mainstream therapy, Strainprint helps medical cannabis patients and doctors to use cannabis in the most effective and responsible way possible. Strainprint^™ data supports global cannabis research and provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharmacies, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store.  www.strainprintanalytics.com. Facebook, Twitter, LinkedIn.

About VIVO Cannabis™

VIVO, based in Napanee, Ontario, is recognized for trusted, high-quality products and services. It holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical™, FIRESIDE™, Canna Farms™ and Lumina™. In August 2018, VIVO acquired Canna Farms Limited, a premium cannabis company based in Hope, British Columbia. Canna Farms was B.C.'s first Licensed Producer and has several years of craft cultivation experience and expertise, as well as a significant patient base and positive cash flow. The Company is significantly expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, including Germany and Australia. VIVO also operates Harvest Medicine, a patient-centric and highly scalable network of specialty medical cannabis clinics as well as a new free telemedicine app that provides best-in-class education and support to over 15,000 patients. VIVO has a healthy balance sheet with over $100 million in cash and is well-positioned to accelerate growth in both Canada and internationally.

More Information
Barry Fishman, CEO: [email protected]
Michael Bumby, CFO: [email protected]
Website: vivocannabis.com

ON BEHALF OF THE BOARD OF DIRECTORS

Barry Fishman (CEO and Director)
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information
This news release contains forward-looking statements, including statements regarding the Company's announced completion of an agreement with OCS and the potential expected benefits of that agreement. The forward-looking statements in this release are based on certain assumptions and involve known and unknown risks and uncertainties and other factors that could cause actual events to differ materially from current assumptions and expectations, including that the agreement with OCS may not lead to any material benefits for the Company, or that OCS will want to renew the contract on an ongoing basis, or that Ontario cannabis consumers will value the FIRESIDE^™ and LUMINA^™ brands. These forward-looking statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements including, but not limited to, that the proposed Canna Farms acquisition may not close on the terms expected or at all; that there may be regulatory impediments to the timing of the opening of the adult use market; and that there may occur changes to industry regulations that are adverse to the Company. A more complete discussion of the risks and uncertainties facing the Company appears in the Company's Annual Information Form and continuous disclosure filings, which are available on SEDAR at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason, other than as required by applicable securities laws.

SOURCE Strainprint Technologies Ltd.

Media Contact: Jessica Moran, 519-494-5379, Strainprint Technologies Ltd., [email protected]